1269232-96-3

Usage

Uses

Used in Synthetic Organic Chemistry:
Benzenamine, 5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is used as a reagent for the synthesis of complex organic molecules, including bioactive molecules and pharmaceutical intermediates. Its unique molecular structure with boron, chlorine, and fluorine components makes it a valuable asset in the development of new compounds with potential applications in various industries.
Used in Advanced Research and Development:
BenzenaMine, 5-chloro-2-fluoro-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)is employed in advanced research and development processes, where its specific properties can be harnessed to create novel molecules with desired characteristics. Its use in these processes is crucial for the advancement of scientific knowledge and the development of new technologies.
Used in Pharmaceutical Industry:
Benzenamine, 5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is used as a reagent in the pharmaceutical industry for the synthesis of pharmaceutical intermediates. These intermediates are essential building blocks in the production of various drugs, contributing to the development of new medications and therapies.
Due to its specific applications and potential hazard, handling of Benzenamine, 5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)should be executed by professionals or under professional supervision to ensure safety and effectiveness in its intended applications.

Upstream product

• 345-18-6 2-fluoro-5-chloronitrobenzene 
• 1269232-95-2 3-bromo-5-chloro-2-fluoroaniline 
• 73183-34-3 bis(pinacol)diborane 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Synthesis of 2 - halo - 3 - [...] borate - 5 - chloroaniline method

The invention discloses a method for synthesizing 2-halogenated-3-pinacol borate-5-chloroaniline and belongs to the field of drug intermediate synthesis. The 2-halogenated-3-pinacol borate-5-chloroaniline is synthesized from 2-halogenated-5-chloro-nitrobenzene, which is used as a raw material and can be provided by the market through three steps of bromization, coupling and reduction; the method provided by the invention is faster in synthesis, simple and effective, and high in yield, and meanwhile, a coarse product obtained in each step can be directly used in the next step; since compared with an amino group, the nitro group is a strong electron withdrawing group, a method that coupling is performed and then reduction is performed in reaction is adopted, and the dosage of a catalyst can be reduced to 1-2 mol% in the second step of coupling, therefore, the reaction cost is further reduced.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.